Martha Arellano MD
Overview
Board certified in hematology, medical oncology and internal medicine, Dr. Arellano specializes in the treatment of leukemia and myelodysplastic syndromes. She started practicing with Emory Healthcare in 2006.
Dr. Arellano is a clinical member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University. She currently leads the Department of Hematology and Medical Oncology's Fellowship program.
Dr. Arellano earned her medical degree from Emory University School of Medicine in Atlanta, Georgia. She went on to complete her internship and residency at Emory University Hospital in Atlanta, Georgia.
Dr. Arellano's primary research focus is in the development of novel therapies for older adults with acute leukemias and myelodysplastic syndromes and immune-based therapies for hematological malignancies.
She is principal investigator on therapeutic trials for patients with acute leukemias and myelodysplastic syndromes, including immunotherapy and allogeneic transplantation. She is also co-investigator on a tissue repository for hematological disorders, a project that leads to collaborations with scientists within and outside of Emory University.
Dr. Arellano has published in a number of leading journals including Journal of Clinical Oncology, Biology of Blood and Marrow Transplantation and Leukemia and Lymphoma.
Dr. Arellano received the 2018 James R. Eckman Award for Teaching Excellence from the Emory Department of Hematology and Medical Oncology Fellowship Program.
Academic Appointment
- Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- MD from Emory University School of Medicine
- Bachelor Degree from Georgia State University
Research
Focus
- Novel therapies for older adults with acute leukemias and myelodysplastic syndromes; immune-based therapies for hematological malignancies.
Publications
-
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial.
Blood Cancer J Volume: 15 Page(s): 55
04/03/2025 Authors: Hoff FW; Huang Y; Welkie RL; Swords RT; Traer E; Stein EM; Lin TL; Patel PA; Collins RH; Baer MR -
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia.
Blood Cancer J Volume: 15 Page(s): 49
03/28/2025 Authors: Pullarkat V; Pratz KW; Dhner H; Recher C; Thirman MJ; DiNardo CD; Fenaux P; Schuh AC; Wei AH; Pigneux A -
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Leukemia
03/19/2025 Authors: Shah BD; Cassaday RD; Park JH; Houot R; Logan AC; Boissel N; Leguay T; Bishop MR; Topp MS; O'Dwyer KM -
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
J Clin Oncol Volume: 43 Page(s): 75 - 84
01/01/2025 Authors: Issa GC; Aldoss I; Thirman MJ; DiPersio J; Arellano M; Blachly JS; Mannis GN; Perl A; Dickens DS; McMahon CM -
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.
N Engl J Med Volume: 391 Page(s): 2219 - 2230
12/12/2024 Authors: Roddie C; Sandhu KS; Tholouli E; Logan AC; Shaughnessy P; Barba P; Ghobadi A; Guerreiro M; Yallop D; Abedi M -
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
Blood Adv Volume: 8 Page(s): 5297 - 5305
10/22/2024 Authors: Hoff FW; Blum WG; Huang Y; Welkie RL; Swords RT; Traer E; Stein EM; Lin TL; Archer KJ; Patel PA -
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
Blood Adv Volume: 8 Page(s): 4209 - 4220
08/13/2024 Authors: DiNardo CD; Roboz GJ; Watts JM; Madanat YF; Prince GT; Baratam P; de Botton S; Stein A; Foran JM; Arellano ML -
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
Target Oncol Volume: 19 Page(s): 321 - 332
05/01/2024 Authors: Maris M; Salles G; Kim WS; Kim TM; Lyons RM; Arellano M; Karmali R; Schiller G; Cull E; Abboud CN -
Ivosidenib in Mutant IDH1 Relapsed/ Refractory Myelodysplastic Syndrome: Updated Substudy Results
Volume: 23 Page(s): S366 - S367
09/01/2023 Authors: DiNardo CD; Roboz GJ; Watts JM; Madanat YF; Prince GT; Baratam P; de Botton S; Stein A; Foran JM; Arellano ML -
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
J Immunother Cancer Volume: 11
08/01/2023 Authors: Shah BD; Cassaday RD; Park JH; Houot R; Oluwole OO; Logan AC; Boissel N; Leguay T; Bishop MR; Topp MS